Antengene Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2018
NCT03591965
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Antengene Biologics Limited | Antengene Corporation | Antengene Therapeutics Limited | Guoxue lane, Chengdu, Sichuan | Medical Monitor | Shanghai Antengene Corporation Limited